Septerna downgraded by Wells Fargo with a new price target
$SEPN
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2025 | $26.00 | Buy | H.C. Wainwright |
| 2/18/2025 | $14.00 | Overweight → Equal Weight | Wells Fargo |
| 11/19/2024 | $38.00 | Overweight | Analyst |
| 11/19/2024 | Buy | TD Cowen | |
| 11/19/2024 | $43.00 | Overweight | Wells Fargo |
| 11/19/2024 | $50.00 | Overweight | Cantor Fitzgerald |